胶质瘤代谢反馈原位研究:二氟甲基鸟氨酸联合AMXT-1501的高分子量微透析首次人体药效学试验
该首次人体药效学试验拟对15例高级别胶质瘤次全切除术后患者给予二氟甲基鸟氨酸(DFMO)联合或不联合AMXT-1501,通过植入残留肿瘤及邻近脑组织的高分子量微透析导管,于术后第1至第5天监测细胞外鸟苷乙酸(GAA)及多胺水平,以确定多胺耗竭的候选药效学生物标志物。
要点
- 高级别胶质瘤细胞外代谢特征中鸟苷乙酸(GAA)富集,与鸟氨酸及多胺合成相关。
- DFMO抑制鸟氨酸脱羧酶(ODC),AMXT-1501为多胺转运体抑制剂,可克服肿瘤对DFMO的耐药。
- 拟通过术后第1至第5天高分子量微透析监测细胞外GAA和多胺,评估多胺耗竭的药效学反馈。
核心结论
- 本试点0期研究将在DFMO联合或不联合AMXT-1501治疗期间提供原位反馈,以确定高级别胶质瘤对多胺耗竭的反应。
- 作者预计肿瘤内GAA相较于邻近脑组织升高,但在DFMO抑制ODC后24小时内下降。
- 若AMXT-1501有效增强ODC抑制的细胞毒性作用,作者预计DFMO联合AMXT-1501治疗相较于单用DFMO时细胞毒性生物标志物(包括谷氨酸)升高。
研究设计与样本
- 首次人体药效学试验,计划纳入15例高级别胶质瘤患者,在临床指征的次全切除术后给予DFMO联合或不联合AMXT-1501。
- 将高分子量微透析导管植入残留肿瘤及邻近脑组织,于术后第1天至第5天治疗干预期间监测细胞外GAA和多胺,第5天出院前拔除导管。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVES: No new drug has improved survival for glioblastoma since temozolomide in 2005, due in part to the relative inaccessibility of each patient's individualized tumor biology and its response to therapy. We have identified a conserved extracellular metabolic signature of enhancing high-grade gliomas enriched for guanidinoacetate (GAA). GAA is coproduced with ornithine, the precursor to protumorigenic polyamines through ornithine decarboxylase (ODC). AMXT-1501 is a polyamine transporter inhibitor that can overcome tumoral resistance to the ODC inhibitor, difluoromethylornithine (DFMO). We will use DFMO with or without AMXT-1501 to identify candidate pharmacodynamic biomarkers of polyamine depletion in patients with high-grade gliomas in situ . We aim to determine (1) how blocking polyamine production affects intratumoral extracellular guanidinoacetate abundance and (2) the impact of polyamine depletion on the global extracellular metabolome within live human gliomas in situ. METHODS: DFMO, with or without AMXT-1501, will be administered postoperatively in 15 patients after clinically indicated subtotal resection for high-grade glioma. High-molecular weight microdialysis catheters implanted into residual tumor and adjacent brain will be used for postoperative monitoring of extracellular GAA and polyamines throughout therapeutic intervention from postoperative day (POD) 1 to POD5. Catheters will be removed on POD5 before discharge. EXPECTED OUTCOMES: We anticipate that GAA will be elevated in tumor relative to adjacent brain although it will decrease within 24 hours of ODC inhibition with DFMO. If AMXT-1501 effectively increases the cytotoxic impact of ODC inhibition, we expect an increase in biomarkers of cytotoxicity including glutamate with DFMO + AMXT-1501 treatment when compared with DFMO alone. DISCUSSION: Limited mechanistic feedback from individual patients' gliomas hampers clinical translation of novel therapies. This pilot Phase 0 study will provide in situ feedback during DFMO + AMXT-1501 treatment to determine how high-grade gliomas respond to polyamine depletion.
引用
- Riviere-Cazaux C, Neth BJ, Hoplin MD, et al. Glioma Metabolic Feedback In Situ: A First-In-Human Pharmacodynamic Trial of Difluoromethylornithine + AMXT-1501 Through High-Molecular Weight Microdialysis. Neurosurgery. 2023. PMID: 37246885. doi:10.1227/neu.0000000000002511
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。